Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Apr. 30, 2024 |
Apr. 30, 2023 |
Apr. 30, 2024 |
Apr. 30, 2023 |
|
| Total Revenue | $ 572,937 | $ 307,843 | $ 997,147 | $ 651,874 |
| Less Cost of Goods Sold | (94,170) | (62,634) | (179,364) | (129,145) |
| Gross Profit | 478,767 | 245,209 | 817,783 | 522,729 |
| Operating Costs and Expenses: | ||||
| Selling, General and Administrative | 1,284,824 | 1,537,181 | 3,685,447 | 2,958,351 |
| Research and Development | 139,689 | 66,447 | 295,924 | 73,280 |
| Write-off of Offering Costs | 2,656,962 | |||
| Loss From Operations | (945,746) | (1,358,419) | (5,820,550) | (2,508,902) |
| Other Expense: | ||||
| Interest Expense | (2,160,299) | (56,937) | (2,331,928) | (96,630) |
| Unrealized Gain on Derivative/Warrant Liability | (12,874) | 656 | 464,373 | 707 |
| Net Loss Available to Common Stockholders | $ (3,118,919) | $ (1,414,700) | $ (7,688,105) | $ (2,604,825) |
| Net Loss per Common Share, Basic | $ (0.70) | $ (0.32) | $ (1.72) | $ (0.59) |
| Net Loss per Common Share, Diluted | $ (0.70) | $ (0.32) | $ (1.72) | $ (0.59) |
| Shares Used in Computing Net Loss per Common Share, Basic | 4,460,535 | 4,430,535 | 4,457,898 | 4,430,535 |
| Shares Used in Computing Net Loss per Common Share, Diluted | 4,460,535 | 4,430,535 | 4,457,898 | 4,430,535 |
| Product [Member] | ||||
| Total Revenue | $ 558,987 | $ 307,843 | $ 980,947 | $ 608,874 |
| Product [Member] | Related Party [Member] | ||||
| Total Revenue | $ 13,950 | |||
| Product Sales Related Parties [Member] | ||||
| Total Revenue | 16,200 | 18,000 | ||
| Consulting Revenue [Member] | ||||
| Total Revenue | $ 25,000 | |||
| X | ||||||||||
- Definition Unrealized gain on series derivative warrant liability. No definition available.
|
| X | ||||||||||
- Definition Writeoff of offering costs. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|